263 related articles for article (PubMed ID: 2280190)
21. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins.
Sun Y; Wu S; Bu G; Onifade MK; Patel SN; LaDu MJ; Fagan AM; Holtzman DM
J Neurosci; 1998 May; 18(9):3261-72. PubMed ID: 9547235
[TBL] [Abstract][Full Text] [Related]
22. Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E.
Rye KA; Bright R; Psaltis M; Barter PJ
J Lipid Res; 2006 May; 47(5):1025-36. PubMed ID: 16452453
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms.
Ordovas JM; Litwack-Klein L; Wilson PW; Schaefer MM; Schaefer EJ
J Lipid Res; 1987 Apr; 28(4):371-80. PubMed ID: 3585172
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice.
Gong JS; Kobayashi M; Hayashi H; Zou K; Sawamura N; Fujita SC; Yanagisawa K; Michikawa M
J Biol Chem; 2002 Aug; 277(33):29919-26. PubMed ID: 12042316
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma.
Yang DS; Smith JD; Zhou Z; Gandy SE; Martins RN
J Neurochem; 1997 Feb; 68(2):721-5. PubMed ID: 9003062
[TBL] [Abstract][Full Text] [Related]
27. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein.
Settasatian N; Barter PJ; Rye KA
J Lipid Res; 2008 Jan; 49(1):115-26. PubMed ID: 17921435
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.
Li H; Dhanasekaran P; Alexander ET; Rader DJ; Phillips MC; Lund-Katz S
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):687-93. PubMed ID: 23413428
[TBL] [Abstract][Full Text] [Related]
29. Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation.
den Hartigh LJ; Altman R; Hutchinson R; Petrlova J; Budamagunta MS; Tetali SD; Lagerstedt JO; Voss JC; Rutledge JC
PLoS One; 2012; 7(11):e50513. PubMed ID: 23209766
[TBL] [Abstract][Full Text] [Related]
30. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution.
Chou CY; Lin YL; Huang YC; Sheu SY; Lin TH; Tsay HJ; Chang GG; Shiao MS
Biophys J; 2005 Jan; 88(1):455-66. PubMed ID: 15475580
[TBL] [Abstract][Full Text] [Related]
31. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
32. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. Impact on receptor binding activity.
Weisgraber KH; Shinto LH
J Biol Chem; 1991 Jun; 266(18):12029-34. PubMed ID: 2050696
[TBL] [Abstract][Full Text] [Related]
33. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects.
Ikewaki K; Zech LA; Brewer HB; Rader DJ
J Lab Clin Med; 2002 Nov; 140(5):369-74. PubMed ID: 12434139
[TBL] [Abstract][Full Text] [Related]
35. Structural and functional variations in human apolipoprotein E3 and E4.
Chou CY; Jen WP; Hsieh YH; Shiao MS; Chang GG
J Biol Chem; 2006 May; 281(19):13333-13344. PubMed ID: 16540478
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics.
Eto M; Watanabe K; Iwashima Y; Morikawa A; Oshima E; Sekiguchi M; Ishii K
Diabetes; 1986 Dec; 35(12):1374-82. PubMed ID: 3770314
[TBL] [Abstract][Full Text] [Related]
37. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid.
LaDu MJ; Lukens JR; Reardon CA; Getz GS
J Neurosci Res; 1997 Jul; 49(1):9-18. PubMed ID: 9211985
[TBL] [Abstract][Full Text] [Related]
38. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.
Fazio S; Horie Y; Weisgraber KH; Havekes LM; Rall SC
J Lipid Res; 1993 Mar; 34(3):447-53. PubMed ID: 8468528
[TBL] [Abstract][Full Text] [Related]
39. The LDL receptor binding domain of apolipoprotein E directs the relative orientation of its C-terminal segment in reconstituted nascent HDL.
Kothari S; Bala N; Patel AB; Donovan A; Narayanaswami V
Biochim Biophys Acta Biomembr; 2021 Jul; 1863(7):183618. PubMed ID: 33831404
[TBL] [Abstract][Full Text] [Related]
40. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
